Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245103 | 0.93 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1TSHR | |
| SCHEMBL2722250 | 0.89 | ALDH1A1 (0.57) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1TSHR | |
| SCHEMBL3673389 | 0.84 | SMN1; SMN2 (0.73) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1HRH1 | |
| SCHEMBL9774 | 0.84 | SMN1; SMN2 (0.68) | CYP1A2SMN1; SMN2CYP2C19HRH1LMNA | |
| SCHEMBL6196923 | 0.84 | SMN1; SMN2 (0.68) | CYP1A2SMN1; SMN2CYP2C19HRH1LMNA | |
| SCHEMBL6687222 | 0.84 | SMN1; SMN2 (0.73) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1HRH1 | |
| SCHEMBL19177065 | 0.83 | CYP1A2 (0.62) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL3513717 | 0.82 | SMN1; SMN2 (0.66) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1HRH1 | |
| SCHEMBL7440930 | 0.82 | SMN1; SMN2 (0.66) | CYP1A2SMN1; SMN2CYP2C19HRH1LMNA | |
| Hydrochloric Acid SCHEMBL7206845 | 0.82 | SMN1; SMN2 (0.71) | CYP1A2SMN1; SMN2CYP2C19ALDH1A1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | claimed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-6534489-B1 | Organophosphorus compounds and the use thereof | JOMAA PHARMAKA GMBH (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-1133500-B1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | JOMAA PHARMAKA GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1133500-A1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | Jomaa Pharmaka GmbH (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031085-A1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | JOMAA PHARMAKA GMBH (DE) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | CYP1A2 278/4885SMN1; SMN2 3865/4885CYP2C19 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.